Not Signed In -
Nalbuphine Injection |
Nubain |
Clinical Trial: Interaction Between Nalbuphine and Morphine in PCA
This study is currently recruiting patients.
Verified by National Taiwan University Hospital June 2005
|
Purpose
- Nalbuphine is opioid mu receptro antagonist and kappa receptor agonist
- This study was designed to investigate the interaction between nalbuphine and morphine
| Condition | Intervention | Phase |
|---|---|---|
| Postoperative Pain | Drug: Nalbuphine and morphine | Phase IV |
MedlinePlus related topics: Pain
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title: Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients
Further Study Details:
Primary Outcomes: analgesic effect
Secondary Outcomes: incidence of opioid-related side effects
Expected Total Enrollment: 200
Secondary Outcomes: incidence of opioid-related side effects
Expected Total Enrollment: 200
Study start: January 2005
- Nalbuphine is opioid mu receptro antagonist and kappa receptor agonist
- This study was designed to investigate the interaction between nalbuphine and morphine
- The analgesic effect and opioid-related side effects will be investigated
Eligibility
Ages Eligible for Study: 18 Years - 65 Years, Genders Eligible for Study: Female
Criteria
Inclusion Criteria:
- Age 18-65 y/o
- Female patients of ASA physical status I to III
- Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor
Exclusion Criteria:
- Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
- Intraoperative fentanyl use > 3 μg/kg
- Patients with definite diagnosis of esophageal reflux syndrome
- Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
- Surgery > 4 hours or laparoscopy surgery
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00155233
Taiwan
National Taiwan University Hospital, Taipei, 100, Taiwan; Recruiting
Yu Chang Yeh, MD cooltony@ha.mc.ntu.edu.tw
Wei-Zen Sun, MD, Principal Investigator
Wei-Zen Sun, MD, Principal Investigator
Study chairs or principal investigators
Wei-Zen Sun, MD, Principal Investigator, National Taiwan University Hospital
More Information
Study ID Numbers: 931002
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00155233
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 9, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00155233
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Nalbuphine Injection (Drug Digest)
- Nubain (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
